Konno S. SX-fraction: Promise for novel treatment of type 2 diabetes. World J Diabetes 2020; 11(12): 572-583 [PMID: 33384765 DOI: 10.4239/wjd.v11.i12.572]
Corresponding Author of This Article
Sensuke Konno, PhD, Associate Professor, Department of Urology, New York Medical College, BSB Room A03, Valhalla, NY 10595, United States. sensuke_konno@nymc.edu
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Dec 15, 2020; 11(12): 572-583 Published online Dec 15, 2020. doi: 10.4239/wjd.v11.i12.572
SX-fraction: Promise for novel treatment of type 2 diabetes
Sensuke Konno
Sensuke Konno, Department of Urology, New York Medical College, Valhalla, NY 10595, United States
Author contributions: Konno S contributed to the entire study and manuscript preparation.
Conflict-of-interest statement: Sensuke Konno declares that there is no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sensuke Konno, PhD, Associate Professor, Department of Urology, New York Medical College, BSB Room A03, Valhalla, NY 10595, United States. sensuke_konno@nymc.edu
Received: July 9, 2020 Peer-review started: July 9, 2020 First decision: October 6, 2020 Revised: October 20, 2020 Accepted: November 11, 2020 Article in press: November 11, 2020 Published online: December 15, 2020 Processing time: 156 Days and 11.7 Hours
Core Tip
Core Tip: We have been searching for a natural agent capable of controlling diabetic conditions in patients with type 2 diabetes for years. We then came across “SX-fraction (SXF)”, isolated from maitake mushroom (Grifola frondorsa), with anti-diabetic and hypoglycemic activities. In this short review, we chronologically described several key studies of SXF such as animal studies using diabetic mice (to demonstrate anti-diabetic activity), limited clinical studies on volunteer patients with type 2 diabetes (to show hypoglycemic activity), and in vitro study using skeletal muscle cells (to elucidate the hypoglycemic mechanism). After all, SXF appears to be a natural, safe, effective agent for treatment of patients with type 2 diabetes, although more (clinical) studies are yet required for confirmation.
